Heghine Khachatryan: New Evidence in Secondary Stroke Prevention: Cilostazol + Aspirin vs Ticagrelor + Aspirin
Heghine Khachatryan, Editor-in-Chief of Hemostasis Today, Head of Hemophilia and Thrombosis Center at Yeolyan Hematology and Oncology Center, shared a post by International Journal of Stroke on LinkedIn:
“New evidence in secondary stroke prevention
A recent study published in the International Journal of Stroke reports that cilostazol plus aspirin significantly reduces recurrent stroke, myocardial infarction, and vascular death, with comparable efficacy to ticagrelor plus aspirin in the acute-phase treatment of large-vessel disease.
Why this matters
• Provides an alternative dual antiplatelet strategy with proven effectiveness
• Particularly relevant for patients with high bleeding risk, intolerance, or contraindications to potent P2Y12 inhibitors
• Highlights the growing role of cilostazol-based regimens beyond East Asian populations
-This study adds valuable data to ongoing discussions on individualized antiplatelet therapy after ischemic stroke and reinforces the need to balance efficacy with safety.
Full article: Ticagrelor plus aspirin versus cilostazol plus aspirin in the acute-phase treatment of large-vessel disease”
Quoting International Journal of Stroke‘s post:
“Study finds cilostazol plus aspirin reduced recurrent stroke, MI, and vascular death with a comparable rate to ticagrelor plus aspirin
However, cilostazol plus aspirin showed significantly lower rates of hemorrhagic complications and better tolerability
Read more here.”
Title: Ticagrelor plus aspirin versus cilostazol plus aspirin in the acute-phase treatment of large-vessel minor stroke or TIA: A randomized controlled multi-center trial, the TACTIS trial
Authors: Mohamed Ismaiel, Sherihan Rezk ahmed et al.
Stay updated and find more posts featuring Heghine Khachatryan on Hemostasis Today.
-
Apr 16, 2026, 09:41Wolfgang Miesbach: Adeno-Associated Virus Neutralizing Antibodies and Their Clinical Impact on Gene Therapy
-
Apr 16, 2026, 09:33Jeyaraj Pandian: Low-Cost Stroke Rehabilitation Technologies at MENA-VINM 2026
-
Apr 16, 2026, 09:21Aurore Ughetto: The Hemocompatibility Burden of Micro-Axial Flow Pump Support
-
Apr 16, 2026, 09:09Naung Latt Htun: High Clinical Suspicion in Acquired Hemophilia A is Essential
-
Apr 16, 2026, 08:58Chittal Raulji: ASH-ISTH 2026 Guidelines for Anticoagulant Prophylaxis for Pediatric VTE Is Now Live in Blood Advances
-
Apr 16, 2026, 08:47Wolfgang Miesbach: Key Open Questions and Clinical Paradoxes in ITP
-
Apr 16, 2026, 08:19M Rafiqul Islam: Post-Thrombectomy Blood Pressure Management in Acute Ischemic Stroke
-
Apr 16, 2026, 06:58Rob Maloney: From Past to Progress in Hemophilia Care in the Dominican Republic
-
Apr 16, 2026, 06:51Michael Ertl: Patient-Reported Outcomes Reveal Differences in Perceived Stroke Recovery